NIH Announces Virtual Meeting with Closed Grant Review
Published Date: 9/24/2025
Notice
Summary
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a two-day virtual meeting on January 26-27, 2026. The first day is open to the public and will share updates and scientific talks, while the second day is closed to review grant applications confidentially. Researchers and the public can join or send comments, with no cost to attend and easy online access.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Open Virtual Session Videocast
The National Advisory Child Health and Human Development Council will hold an open virtual session on January 26, 2026, from 12:00 p.m. to 5:00 p.m. You can watch the open session via the NIH Videocasting and Podcasting website, and registration is not required to attend the open portion.
Public May File Written Comments
Any interested person may file written comments with the committee by forwarding a statement to the Contact Person listed in the notice. The statement should include the name, address, telephone number and, when applicable, the business or professional affiliation of the person.
Accessibility Accommodations Available
If you need special assistance—such as sign language interpretation or other reasonable accommodations—to attend, you must notify the Contact Person listed in the notice in advance of the meeting. Contact details include Rebekah S. Rasooly, phone 301-827-2599 and the listed email/address.
Closed Grant Review Protects Confidentiality
The council will hold a closed session on January 27, 2026, from 9:00 a.m. to 12:00 p.m. to review and evaluate grant applications and proposals. The meeting is closed under 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, patentable material, and personal information of applicants.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-18464, Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is hosting a hybrid meeting on May 4, 2026, about medical rehabilitation research. Anyone interested can join in person or online, share ideas, or even speak at the meeting. This is a great chance for scientists, patients, and the public to get involved and help shape future research without any registration fees.
Next: 2025-18468, Computer Software Assurance for Production and Quality System Software; Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just released new guidance to help medical device makers use computer software safely and smartly during production and quality checks. This update encourages using fresh tech to make devices better and faster while keeping everything legal and safe. If you work with medical device software, get ready to follow these new tips to stay ahead and keep patients happy!